BIOBLOOM LIFE LIMITED

What BIOBLOOM LIFE LIMITED does

BioBloom Life Limited (legal entity BioBloom Ltd, registered at Silverstream House, 45 Fitzroy Street, London) is a University of Cambridge spin-out founded in 2023 that provides an endometrial microbiome diagnostic service for fertility and gynaecology clinicians. The company's core product is a laboratory assay that uses 16S rRNA gene sequencing and a bioinformatics pipeline specifically developed for low-biomass endometrial samples, with negative controls, reagent-contaminant subtraction, minimum-biomass thresholds, and species-level Lactobacillus resolution (distinguishing L. crispatus from L. iners). All sequencing and bioinformatic analysis are performed at the University of Cambridge genomics laboratory; reports classify samples as Lactobacillus-dominant, intermediate, dysbiotic, or low biomass and are delivered via a private clinic portal.

The business model is B2B laboratory services: tests are ordered exclusively through partner fertility and gynaecology clinics (no direct-to-patient channel), with revenue generated from diagnostic testing fees paid by partner clinics. The referring clinic is the data controller for the patient's clinical record while BioBloom Ltd acts as a processor; sample identifiers are pseudonymised before sequencing, and the company operates under UK GDPR. Distribution is entirely UK-based, currently via a clinical pilot launched in 2026 with NHS-affiliated and private fertility clinics, plus an explicit second segment of gynaecology practices investigating recurring bacterial vaginosis, recurrent UTIs, and chronic discomfort. Marketing is conducted exclusively to healthcare professionals through clinical education content, a curated research library of 16 papers (2015-2025), and clinic-registration pathways, rather than direct-to-consumer channels. Pricing is not publicly disclosed.

Name

BIOBLOOM LIFE LIMITED

Legal name

BioBloom Ltd

Website

https://biobloomlife.com

Company type

Private

Founded year

2023

Operating status

Operating

Short description

BioBloom Life, a University of Cambridge spin-out, provides a B2B endometrial microbiome diagnostic assay using 16S rRNA sequencing to UK fertility and gynaecology clinics, supporting treatment decisions for implantation failure, recurrent pregnancy loss, and recurring infections.

Ownership category

akta.pro rank

Product category

Reproductive Health Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Microbiome & Metagenomics Services (HLAGANAH)

akta.pro secondary industries

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Endometrial microbiome diagnostics
• Clinical genomic sequencing
• Fertility diagnostic services
• Microbiome laboratory testing
• Reproductive health diagnostics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Laboratory Diagnostic Service: BioBloom provides endometrial microbiome diagnostic testing as a laboratory service ordered through partner fertility and gynaecology clinics. The referring clinic remains the data controller for the patient's clinical record; BioBloom Ltd acts as a processor for the laboratory analysis and the resulting report. Revenue is generated through diagnostic testing fees from partner clinics, not directly from patients.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

BioBloom Life provides an Endometrial Microbiome Assay — a laboratory diagnostic service that uses 16S rRNA gene sequencing and a bioinformatics pipeline to characterise the microbial composition of endometrial samples. Tests are ordered by fertility or gynaecology specialists at partner clinics, samples are processed at the University of Cambridge genomics laboratory, and results are returned to the ordering clinician through a private portal to support treatment decisions in IVF, recurrent implantation failure, recurrent pregnancy loss, and gynaecological conditions such as recurring BV and UTIs.

Product overview

BioBloom Life offers a single core diagnostic product: the Endometrial Microbiome Assay. This is a laboratory service that uses 16S rRNA gene sequencing and bioinformatics to characterize the microbial environment inside the uterine cavity. The test is ordered through partner fertility and gynaecology clinics; patients cannot self-refer. Samples are collected in-clinic via transcervical catheter and analyzed at Cambridge genomics laboratories. Results are delivered as species-level reports via a private clinic portal, supporting targeted treatment decisions for dysbiotic profiles.

Differentiator

Problem solved

Functional benefit

Products and services

• Endometrial Microbiome Assay A laboratory diagnostic service using 16S rRNA gene sequencing and a bioinformatics pipeline to characterise the endometrial microbiome composition for fertility and gynaecology specialists. Samples are collected in-clinic via transcervical catheter, processed at the University of Cambridge genomics laboratory, and returned as clinician-ready reports (Lactobacillus-dominant, intermediate, dysbiotic, or low biomass) via a private clinic portal. The test is ordered exclusively through partner fertility and gynaecology clinics and is not available direct-to-patient.

Quantifiable outcome

• Live birth rate 58.8% with Lactobacillus-dominant endometrium vs 6.7% without (Moreno 2016, n=35)
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• UK Fertility Consultants and EmbryologistscoreStrategic or Co-development Partner · 1 January 2025Methodology validated in 2025 in partnership with UK fertility consultants and embryologists. Test development has been shaped by direct input from practising fertility specialists and embryologists.
• University of CambridgecoreStrategic or Co-development PartnerBioBloom Life is a University of Cambridge spin-out. The sequencing methodology was developed in the University of Cambridge genomics laboratory and refined with practising fertility consultants. The company maintains academic collaboration for assay improvement and peer-reviewed research publications.
• Partner Fertility Clinics (UK)coreStrategic or Co-development PartnerPartner fertility and gynaecology clinics across the UK that order BioBloom's endometrial microbiome test. Testing methodology decisions are shaped by clinical reality through direct collaboration with consultants, embryologists, and gynaecologists. Clinical pilot includes NHS-affiliated and private fertility clinics.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Evvy: Evvy offers vaginal microbiome testing with sequencing-based analytics and clinician-facing reporting for women's health; directly comparable to BioBloom in the women's microbiome diagnostics category, though focused on vaginal rather than endometrial sampling.
• Daye: Daye is a UK-based women's health diagnostics company offering at-home vaginal microbiome and STI testing; comparable in sequencing-based women's microbiome diagnostics and overlapping UK clinician/clinic channels.
• Juno Bio: Juno Bio provides vaginal microbiome testing services for reproductive and gynaecological health using 16S rRNA sequencing; comparable as a microbiome diagnostics service targeting reproductive-age women with a similar B2B clinical channel.

Emerging players

• Maat Pharma: Maat Pharma develops microbiome-based therapeutics anchored on gut microbiome analytics and clinical translation; comparable as a microbiome-driven clinical development company building translation between microbiome science and patient care.

Broad incumbents

• CooperSurgical: CooperSurgical is a large reproductive health diagnostics and medical device company supplying IVF clinics globally; a broader incumbent in the fertility clinic supply ecosystem in which BioBloom's endometrial microbiome test would be ordered.
• Hologic: Hologic is a major molecular diagnostics and women's health company with established lab infrastructure and gynaecological testing menus; relevant as a broad incumbent in women's health molecular diagnostics that could extend into microbiome-based offerings.
• LabCorp (Clinical Trials / Specialty Labs): LabCorp operates global specialty laboratory services including women's health and reproductive diagnostics; a broad incumbent with central lab capability that could host endometrial microbiome assays alongside existing reproductive test menus.
• Igenomix (Vitrolife): Igenomix, now part of Vitrolife, provides reproductive genetics and genomics services to IVF clinics globally; comparable as a sequencing-based diagnostic services provider selling into the same fertility clinic channel at much greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biobloom-life

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOBLOOM LIFE LIMITED